Key result
In patients undergoing total hip replacement, LMWH reduced non-fatal pulmonary embolism compared to placebo (OR 0.14; 95% CI 0.03-0.74; p=0.029) but increased haematoma formation.
Why the study?
Does in-patient LMWH reduce venous thromboembolic events and mortality compared to placebo in patients undergoing total hip replacement?
Meta-Analysis
Does in-patient LMWH reduce venous thromboembolic events and mortality compared to placebo in patients undergoing total hip replacement?
Odds Ratio: 0.14 (95% CI 0.03–0.74)
p-value: p=0.029
In patients undergoing total hip replacement, LMWH reduces non-fatal pulmonary embolism but increases haematoma formation without affecting mortality, suggesting limited benefit in patients without additional thromboembolic risk factors.
No takes yet. Share an insight, caveat, or question.
LMWH may warrant selective use in high-risk patients only; challenges routine prophylaxis without mortality benefit in standard-risk total hip replacement.
Tasker et al. (2010) conducted a meta-analysis in Total hip replacement. Low molecular weight heparin (LMWH) vs. Placebo was evaluated on non-fatal pulmonary embolism (PE) (OR 0.14, 95% CI 0.03 to 0.74, p=0.029). In patients undergoing total hip replacement, LMWH reduced non-fatal pulmonary embolism compared to placebo (OR 0.14; 95% CI 0.03-0.74; p=0.029) but increased haematoma formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: